Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Sunday, January 11, 2026

JPM 2026 Schedule Through A Molecular Tools & Testing Lens

›
The J.P. Morgan Healthcare Conference is this week in San Francisco.  As with every other one, I'm tracking any news remotely from Bosto...
Friday, January 09, 2026

Stalking the Elusive Product Market Fit

›
I had a wonderful breakfast conversation back in November with Arima Genomics Founder (and now President and Chief Operating Officer) Sid Se...
1 comment:
Wednesday, January 07, 2026

Scales of Instrumentation and Automation

›
Back in September I moved into a product role within the automation unit at Ginkgo, where we sell autonomous laboratories.  I'm going to...
3 comments:
Sunday, January 04, 2026

Sequencing Instrument Outlook 2026

›
3 comments:
Monday, December 29, 2025

The Joy of Rediscovery

›
A key goal of science is to discover new information, and it is one of the great joys of science to believe you have done so.  Sometimes it ...
4 comments:
Tuesday, December 16, 2025

UltraMarathonRT: When Your Reverse Transcription Must Go Long

›
The 1960s, 1970s and 1980s were both the early years and golden years for nucleic acid enzymology. Scientists unraveling the secrets of DNA ...
1 comment:
Thursday, December 04, 2025

Countable Labs: New Approach to Enumerating DNA

›
Countable Labs, formerly Enumerix, was founded by serial entrepreneur Stephen Fodor, who originally stormed on the molecular tools scene wit...
2 comments:
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.